Lilly KRASes Amgen and Mirati's party
 

AACR Recap

Merck, Moderna show off therapeutic cancer vax data, with phase 3 launch before year-end

By Max Bayer

Merck and Moderna are rapidly accelerating plans for a phase 3 trial of their cancer vaccine-Keytruda combo, hoping to launch a phase 3 trial before the end of the year. The companies found that the combination reduced the risk of recurrence or death in patients with melanoma by 44% compared to Keytruda alone.

Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin

By Angus Liu

Roche has detailed Tecentriq’s performance in early-stage liver cancer from a positive phase 3 trial. But a negative sign of patient deaths might raise some eyebrows, and it could force the company to delay a potential FDA filing.

Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'

By Annalee Armstrong

KRAS inhibitors arrived on the market in May 2021 and December 2022 to much fanfare—but if you ask Eli Lilly’s Loxo unit, the therapies have left much to be desired.

Adela’s multi-cancer blood test shows promise in detecting early stage tumors

By Conor Hale

Canadian newcomer Adela has shown that its test for detecting the faint traces of cancer in the bloodstream could spot 12 different types of the disease, including many in their early stages when they have the best chances of being treated.

Affimed changes path after hitting middle of the road for lymphoma therapy

By Gabrielle Masson

The pressure to perform is building for Affimed as its investigational lymphoma treatment fails to beat current standard-of-care treatments, prompting the German biotech to pursue a new path for its lead asset.

AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate

By Angus Liu

AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable non-small cell lung cancer. But the data raise more questions than answers.

Kinnate ends cancer data wait but fails to captivate investors

By Nick Paul Taylor

The long wait for clinical data on Kinnate Biopharma’s pan-RAF inhibitors is over—and investors see little to get excited about.

Merck's Keytruda clashes with AstraZeneca's Imfinzi in biliary tract cancer

By Angus Liu

Merck didn’t give AstraZeneca much time to celebrate what was immunotherapy’s only win in biliary tract cancer. The New Jersey pharma has shared detailed results for Keytruda as part of an initial treatment after AZ's recent FDA approval for Imfinzi.